Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 9968969Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2024
Linked Award Amount
$2M
Full award amounts, FY2024
Award Records
2
Records listing this PI
Award-Linked Rank
#5,127
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2024 award records by amount
NIH award records listing Michael Ohlmeyer as a PI. Multi-PI records show the full award amount for context.
- 2R44AG071040-02R44Direct protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeutics$1.7Maward amount
- 75N91024C00009-0-9999-1N43SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS$355Kaward amount
Award organization
Organizations that administered FY2024 awards listing Michael Ohlmeyer as a PI.
FY2024 award administered by Atux Iskay Group LLC (NJ).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardAtux Iskay Group LLC
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #5127